GMCN-508A
/ Genmedicn Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 18, 2023
A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants
(clinicaltrials.gov)
- P1 | N=5 | Recruiting | Sponsor: First Affiliated Hospital of Guangxi Medical University | Not yet recruiting ➔ Recruiting
Enrollment open • Gene therapy • Viral vector • Beta-Thalassemia • Gene Therapies • Genetic Disorders • Transplantation
March 07, 2023
A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants
(clinicaltrials.gov)
- P1 | N=5 | Not yet recruiting | Sponsor: First Affiliated Hospital of Guangxi Medical University
Gene therapy • New P1 trial • Viral vector • Beta-Thalassemia • Gene Therapies • Genetic Disorders • Transplantation
1 to 2
Of
2
Go to page
1